{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:13Z","timestamp":1790774653356,"version":"4.1.0"},"reference-count":130,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003451","name":"University of the Basque Country","doi-asserted-by":"publisher","award":["PIF 15\/245"],"award-info":[{"award-number":["PIF 15\/245"]}],"id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI17\/00250"],"award-info":[{"award-number":["FI17\/00250"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01841"],"award-info":[{"award-number":["PI17\/01841"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS18\/00181"],"award-info":[{"award-number":["DTS18\/00181"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01355"],"award-info":[{"award-number":["PI19\/01355"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Department from Basque Country","award":["2017222021"],"award-info":[{"award-number":["2017222021"]}]},{"name":"Health Department from Basque Country","award":["2018222021"],"award-info":[{"award-number":["2018222021"]}]},{"name":"Health Department from Basque Country","award":["2020333008"],"award-info":[{"award-number":["2020333008"]}]},{"name":"Biomedical Research Networking Center on Neurodegenerative Diseases","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myotonic dystrophy type 1 (DM1) is a multisystemic disorder of genetic origin. Progressive muscular weakness, atrophy and myotonia are its most prominent neuromuscular features, while additional clinical manifestations in multiple organs are also common. Overall, DM1 features resemble accelerated aging. There is currently no cure or specific treatment for myotonic dystrophy patients. However, in recent years a great effort has been made to identify potential new therapeutic strategies for DM1 patients. Metformin is a biguanide antidiabetic drug, with potential to delay aging at cellular and organismal levels. In DM1, different studies revealed that metformin rescues multiple phenotypes of the disease. This review provides an overview of recent findings describing metformin as a novel therapy to combat DM1 and their link with aging.<\/jats:p>","DOI":"10.3390\/ijms23052901","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:21:16Z","timestamp":1646648476000},"page":"2901","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting Myotonic Dystrophy Type 1 with Metformin"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2975-934X","authenticated-orcid":false,"given":"Mikel","family":"Garc\u00eda-Puga","sequence":"first","affiliation":[{"name":"Neuromuscular Diseases Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain"},{"name":"Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain"},{"name":"Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED-CIBER), Carlos III Institute, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Saenz-Anto\u00f1anzas","sequence":"additional","affiliation":[{"name":"Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Matheu","sequence":"additional","affiliation":[{"name":"Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain"},{"name":"Basque Foundation for Science (IKERBASQUE), 48009 Bilbao, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Fragilidad y Envejecimiento Saludable (CIBERfes), Carlos III Institute, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-4032","authenticated-orcid":false,"given":"Adolfo","family":"L\u00f3pez de Munain","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain"},{"name":"Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED-CIBER), Carlos III Institute, 28031 Madrid, Spain"},{"name":"Neurology Department, Donostia University Hospital, OSAKIDETZA, 20014 San Sebastian, Spain"},{"name":"Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country, 20014 San Sebastian, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"ref_1","unstructured":"Harper, P.S. (2001). Myotonic Dystrophy, London WB Saunders. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/mus.26194","article-title":"Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis","volume":"58","author":"Emparanza","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/355548a0","article-title":"Cloning of the essential myotonic dystrophy region and mapping of the putative defect","volume":"355","author":"Aslanidis","year":"1992","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0960-8966(95)00040-2","article-title":"A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): A challenge for future molecular studies","volume":"6","author":"Meola","year":"1996","journal-title":"Neuromuscul. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ana.410350305","article-title":"Myotonic dystrophy with no trinucleotide repeat expansion","volume":"35","author":"Thornton","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/NEN.0b013e31816b4acc","article-title":"Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy","volume":"67","author":"Bassez","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol. Clin."},{"key":"ref_9","first-page":"222","article-title":"Myotonic dystrophy type 2: The 2020 update","volume":"39","author":"Meola","year":"2020","journal-title":"Acta Myol."},{"key":"ref_10","first-page":"185","article-title":"Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert\u2019s disease","volume":"35","author":"Almendrote","year":"2020","journal-title":"Neurologia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.43.8.1573","article-title":"Prevalence of myotonic dystrophy in Guip\u00fazcoa (Basque Country, Spain)","volume":"43","author":"Blanco","year":"1993","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.nmd.2012.05.017","article-title":"Epidemiological surveillance of myotonic dystrophy type 1: A 25-year population-based study","volume":"22","author":"Mathieu","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/hmg\/7.2.307","article-title":"Progression of somatic CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients","volume":"7","author":"Martorell","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fgene.2018.00601","article-title":"Repeat interruptions modify age at onset in myotonic dystrophy type 1 by stabilizing DMPK expansions in somatic cells","volume":"9","year":"2018","journal-title":"Front. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Peric, S., Pesovic, J., Savic-Pavicevic, D., Stojanovic, V.R., and Meola, G. (2022). Molecular and clinical implications of variant repeats in myotonic dystrophy type 1. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010354"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.54.6.1218","article-title":"New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1)","volume":"54","author":"Ashizawa","year":"2000","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification","volume":"172","author":"Dogan","year":"2016","journal-title":"Rev. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20246","DOI":"10.1074\/jbc.270.35.20246","article-title":"Identification, tissue-specific expression, and subcellular localization of the 80- and 71-kDa forms of myotonic dystrophy kinase protein","volume":"270","author":"Maeda","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ng0796-325","article-title":"Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy","volume":"13","author":"Reddy","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ng0796-316","article-title":"Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice","volume":"13","author":"Jansen","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.94.14.7388","article-title":"Expansion of a CUG trinucleotide repeat in the 3\u2032 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts","volume":"94","author":"Davis","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ana.10763","article-title":"Ribonuclear Inclusions in Skeletal Muscle in Myotonic Dystrophy Types 1 and 2","volume":"54","author":"Mankodi","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/nar\/29.13.2766","article-title":"In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts","volume":"29","author":"Fardaei","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.celrep.2015.07.029","article-title":"MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain","volume":"12","author":"Goodwin","year":"2015","journal-title":"Cell Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ana.23992","article-title":"Splicing biomarkers of disease severity in myotonic dystrophy","volume":"74","author":"Nakamori","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Mart\u00ednez, A., Soblechero-Mart\u00edn, P., De-La-puente-ovejero, L., Nogales-Gadea, G., and Arechavala-Gomeza, V. (2020). An overview of alternative splicing defects implicated in myotonic dystrophy type i. Genes, 11.","DOI":"10.3390\/genes11091109"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ajhg.2017.01.033","article-title":"CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy","volume":"100","author":"Lanni","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.410350116","article-title":"Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes","volume":"35","author":"Thornton","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/eurheartj\/ehu157","article-title":"Cardiac involvement in myotonic dystrophy: A nationwide cohort study","volume":"35","author":"Lund","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijcard.2015.03.069","article-title":"Myotonic dystrophy and the heart: A systematic review of evaluation and management","volume":"184","author":"Lau","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.4081\/ejh.2012.e36","article-title":"Skeletal muscle features in myotonic dystrophy and sarcopenia: Do similar nuclear mechanisms lead to skeletal muscle wasting?","volume":"56","author":"Malatesta","year":"2012","journal-title":"Eur. J. Histochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.4081\/ejh.2010.e44","article-title":"Structural and functional alterations of the cell nucleus in skeletal muscle wasting: The evidence in situ","volume":"54","author":"Malatesta","year":"2010","journal-title":"Eur. J. Histochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jnp.12192","article-title":"Age-related cognitive decline in myotonic dystrophy type 1: An 11-year longitudinal follow-up study","volume":"14","author":"Labayru","year":"2020","journal-title":"J. Neuropsychol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/acn3.51163","article-title":"Neurodegeneration trajectory in pediatric and adult\/late DM1: A follow-up MRI study across a decade","volume":"7","author":"Labayru","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jns.2008.08.037","article-title":"A cross-sectional study for glucose intolerance of myotonic dystrophy","volume":"276","author":"Matsumura","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3389\/fneur.2019.01229","article-title":"Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1","volume":"10","author":"Nieuwenhuis","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.24540","article-title":"Metabolic syndrome in patients with myotonic dystrophy type 1","volume":"52","author":"Vujnic","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00415-011-6277-5","article-title":"Endocrine function in 97 patients with myotonic dystrophy type 1","volume":"259","author":"Duno","year":"2012","journal-title":"J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mus.21484","article-title":"Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy","volume":"41","author":"Shieh","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1590\/0004-282X20150218","article-title":"Myotonic dystrophy type 1: Frequency of ophthalmologic findings","volume":"74","author":"Ikeda","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/humrep\/17.6.1578","article-title":"Increased (CTG\/CAG)n lengths in myotonic dystrophy type 1 and Machado-Joseph disease genes in idiopathic azoospermia patients","volume":"17","author":"Pan","year":"2002","journal-title":"Hum. Reprod."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/clinem\/dgaa041","article-title":"CTG expansion in the DMPK gene: Semen quality assessment and outcome of preimplantation genetic diagnosis","volume":"105","author":"Puy","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11940-016-0434-1","article-title":"Myotonic Dystrophy Type 1 Management and Therapeutics","volume":"18","author":"Smith","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1212\/WNL.0000000000003124","article-title":"Cancer risk in DM1 is sex-related and linked to miRNA-200\/141 downregulation","volume":"87","author":"Emparanza","year":"2016","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1001\/jama.2011.1796","article-title":"Cancer Risk Among Patients With Myotonic Muscular Dystrophy","volume":"306","author":"Gadalla","year":"2011","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mus.25145","article-title":"A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy","volume":"54","author":"Abbott","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1016\/j.lpm.2013.01.052","article-title":"Augmentation du risque de tumeurs dans la dystrophie myotonique de type 1","volume":"42","author":"Mohamed","year":"2013","journal-title":"Presse Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mayocp.2011.09.005","article-title":"Increased cancer risks in myotonic dystrophy","volume":"87","author":"Win","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10552-009-9395-y","article-title":"Hypothesis: Neoplasms in myotonic dystrophy","volume":"20","author":"Mueller","year":"2009","journal-title":"Cancer Causes Control"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/brain\/121.8.1557","article-title":"Age and causes of death in adult-onset myotonic dystrophy","volume":"121","author":"Thijs","year":"1998","journal-title":"Brain"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaneurol.2017.4778","article-title":"Development and validation of a newscoring system to predict survival in patients with myotonic dystrophy type 1","volume":"75","author":"Wahbi","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_54","first-page":"125","article-title":"Muscle wasting in myotonic dystrophies: A model of premature aging","volume":"7","author":"Goicoechea","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fneur.2018.00601","article-title":"Myotonic dystrophy\u2014A progeroid disease?","volume":"9","author":"Meinke","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Blasco","year":"2013","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1172\/JCI64081","article-title":"GSK3\u03b2 mediates muscle pathology in myotonic dystrophy","volume":"122","author":"Jones","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2353\/ajpath.2009.080560","article-title":"Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells","volume":"174","author":"Bigot","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2990.2009.01014.x","article-title":"Satellite cell dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1","volume":"35","author":"Thornell","year":"2009","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41419-020-02756-8","article-title":"MBNL1 reverses the proliferation defect of skeletal muscle satellite cells in myotonic dystrophy type 1 by inhibiting autophagy via the mTOR pathway","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/MCB.21.20.6927-6938.2001","article-title":"Molecular Basis for Impaired Muscle Differentiation in Myotonic Dystrophy","volume":"21","author":"Timchenko","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/hmg\/10.19.2079","article-title":"Defective satellite cells in congenital myotonic dystrophy","volume":"10","author":"Furling","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_63","first-page":"275","article-title":"Premature senescence in primary muscle cultures of myotonic dystrophy type 2 is not associated with p16 induction","volume":"58","author":"Renna","year":"2014","journal-title":"Eur. J. Histochem."},{"key":"ref_64","first-page":"1763","article-title":"mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1","volume":"126","author":"Denis","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fneur.2018.00368","article-title":"Abnormalities in skeletal muscle myogenesis, growth, and regeneration in myotonic dystrophy","volume":"9","author":"Ausems","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2990.2004.00602.x","article-title":"Expression of late myogenic differentiation markers in sarcoplasmic masses of patients with myotonic dystrophy","volume":"31","author":"Vattemi","year":"2005","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/acn3.50954","article-title":"Leukocyte telomere length in patients with myotonic dystrophy type I: A pilot study","volume":"7","author":"Wang","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-510X(98)00290-1","article-title":"Decreased expression of myotonic dystrophy protein kinase and disorganization of sarcoplasmic reticulum in skeletal muscle of myotonic dystrophy","volume":"162","author":"Ueda","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0361-9230(01)00653-0","article-title":"Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy","volume":"56","author":"Siciliano","year":"2001","journal-title":"Brain Res. Bull."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S979","DOI":"10.1007\/s100720070014","article-title":"Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: New diagnostic approaches for new rationale therapeutics","volume":"21","author":"Tedeschi","year":"2000","journal-title":"Neurol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.18632\/aging.103022","article-title":"Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin","volume":"12","author":"Matheu","year":"2020","journal-title":"Aging"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/hmg\/ddp058","article-title":"Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy","volume":"18","author":"Osborne","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng704","article-title":"Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy","volume":"29","author":"Savkur","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Renna, L.V., Bos\u00e8, F., Brigonzi, E., Fossati, B., Meola, G., and Cardani, R. (2019). Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214254"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11010-013-1681-z","article-title":"Alternative splicing of human insulin receptor gene (INSR) in type i and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2","volume":"380","author":"Santoro","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: Historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1039\/CT9222101790","article-title":"The preparation of methylguanidine, and of \u03b2\u03b2- dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively","volume":"121","author":"Werner","year":"1922","journal-title":"J. Chem. Soc. Trans."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a position statement of the american diabetes association and the european association for the study of diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"eLife"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin-Mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s40261-017-0564-6","article-title":"Lactate Levels with Chronic Metformin Use: A Narrative Review","volume":"37","author":"Huang","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.117.031735","article-title":"Repurposing Metformin for Cardiovascular Disease","volume":"137","author":"Rena","year":"2018","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fendo.2018.00400","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2018.01236","article-title":"Metformin and autoimmunity: A \u201cnew deal\u201d of an old drug","volume":"9","author":"Ursini","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2020.04.001","article-title":"Benefits of Metformin in Attenuating the Hallmarks of Aging","volume":"32","author":"Kulkarni","year":"2020","journal-title":"Cell Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","article-title":"Metformin as a Tool to Target Aging","volume":"23","author":"Barzilai","year":"2016","journal-title":"Cell Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tem.2019.07.015","article-title":"Metformin as Anti-Aging Therapy: Is It for Everyone?","volume":"30","author":"Soukas","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101203","DOI":"10.1016\/j.diabet.2020.09.009","article-title":"Targeting ageing and preventing organ degeneration with metformin","volume":"47","author":"Sunjaya","year":"2021","journal-title":"Diabetes Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.4161\/cc.7.17.6625","article-title":"Metformin slows down aging and extends life span of female SHR mice","volume":"7","author":"Anisimov","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/ncomms3192","article-title":"Metformin improves healthspan and lifespan in mice","volume":"4","author":"Mercken","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","article-title":"Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism","volume":"153","author":"Cabreiro","year":"2013","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","article-title":"Metformin therapy in a transgenic mouse model of Huntington\u2019s disease","volume":"411","author":"Ma","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1","volume":"71","author":"Regazzetti","year":"2011","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/acel.12075","article-title":"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK\/NF-\u03baB activation","volume":"12","author":"Moiseeva","year":"2013","journal-title":"Aging Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrgentox.2018.01.007","article-title":"Metformin: Prevention of genomic instability and cancer: A review","volume":"827","author":"Najafi","year":"2018","journal-title":"Mutat. Res.\u2014Genet. Toxicol. Environ. Mutagen."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.13262","article-title":"Epigenetic effects of metformin: From molecular mechanisms to clinical implications","volume":"20","author":"Bridgeman","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","article-title":"Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells","volume":"25","author":"Neumann","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e31268","DOI":"10.7554\/eLife.31268","article-title":"Metformin extends C. Elegans lifespan through lysosomal pathway","volume":"6","author":"Chen","year":"2017","journal-title":"eLife"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1007\/s00125-017-4349-5","article-title":"Metformin and ageing: Improving ageing outcomes beyond glycaemic control","volume":"60","author":"Valencia","year":"2017","journal-title":"Diabetologia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/dom.12354","article-title":"Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls","volume":"16","author":"Bannister","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/gerona\/glu073","article-title":"Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis","volume":"69","author":"Cheng","year":"2014","journal-title":"J. Gerontol.\u2014Ser. A Biol. Sci. Med. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/1440-1681.12265","article-title":"Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus","volume":"41","author":"Guo","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-131901","article-title":"Long-term metformin usage and cognitive function among older adults with diabetes","volume":"41","author":"Ng","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e12723","DOI":"10.1111\/acel.12723","article-title":"Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults","volume":"17","author":"Kulkarni","year":"2018","journal-title":"Aging Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/geroni\/igx004.2682","article-title":"Targeting aging with metformin (TAME)","volume":"1","author":"Barzilai","year":"2017","journal-title":"Innov. Aging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41586-019-1365-2","article-title":"From discoveries in ageing research to therapeutics for healthy ageing","volume":"571","author":"Campisi","year":"2019","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11357-018-0042-y","article-title":"A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: Report from the TAME Biomarkers Workgroup","volume":"40","author":"Justice","year":"2018","journal-title":"GeroScience"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ijc.32801","article-title":"Diabetes, metformin and cancer risk in myotonic dystrophy type I","volume":"147","author":"Alsaggaf","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1464-5491.2005.01432.x","article-title":"Low-dose metformin improves hyperglycaemia related to myotonic dystrophy","volume":"22","author":"Kouki","year":"2005","journal-title":"Diabet. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: A randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1038\/mtna.2015.35","article-title":"In vitro and in vivo modulation of alternative splicing by the biguanide metformin","volume":"4","author":"Laustriat","year":"2015","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1172\/JCI89616","article-title":"Targeting deregulated AMPK\/mTORC1 pathways improves muscle function in myotonic dystrophy type 1","volume":"127","author":"Brockhoff","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1093\/hmg\/ddy245","article-title":"Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles","volume":"27","author":"Jasmin","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Huguet, A., Medja, F., Nicole, A., Vignaud, A., Guiraud-Dogan, C., Ferry, A., Decostre, V., Hogrel, J.Y., Metzger, F., and Hoeflich, A. (2012). Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying >1000 CTG Repeats from the Human DM1 Locus. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1003043"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: An update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/brv.12674","article-title":"The hallmarks of myotonic dystrophy type 1 muscle dysfunction","volume":"96","author":"Ozimski","year":"2021","journal-title":"Biol. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JND-180329","article-title":"Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015","volume":"5","author":"Gagnon","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"18591","DOI":"10.1073\/pnas.2005748117","article-title":"Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS\/FTD mice","volume":"117","author":"Zu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1073\/pnas.1013343108","article-title":"Non-ATG\u2013initiated translation directed by microsatellite expansions","volume":"108","author":"Zu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e38744","DOI":"10.7554\/eLife.38744","article-title":"Metformin reverses early cortical network dysfunction and behavior changes in Huntington\u2019s disease","volume":"7","author":"Arnoux","year":"2018","journal-title":"eLife"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Herv\u00e1s, D., Forn\u00e9s-Ferrer, V., G\u00f3mez-Escribano, A.P., Sequedo, M.D., Peir\u00f3, C., Mill\u00e1n, J.M., and V\u00e1zquez-Manrique, R.P. (2017). Metformin intake associates with better cognitive function in patients with Huntington\u2019s disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179283"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nm.4335","article-title":"Metformin ameliorates core deficits in a mouse model of fragile X syndrome","volume":"23","author":"Gantois","year":"2017","journal-title":"Nat. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1002\/mgg3.956","article-title":"Metformin treatment in young children with fragile X syndrome","volume":"7","author":"Biag","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.drudis.2021.03.024","article-title":"Myotonic dystrophy type 1 drug development: A pipeline toward the market","volume":"26","author":"Artero","year":"2021","journal-title":"Drug Discov. Today"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2901\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:33:30Z","timestamp":1760135610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":130,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23052901"],"URL":"https:\/\/doi.org\/10.3390\/ijms23052901","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]}}}